Compare Advanced Drainage Systems Inc (WMS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Drainage Systems Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Advanced Drainage Systems Inc trades at $143.04 (market cap $10.96B), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: Advanced Drainage Systems Inc pays a 0.56% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Advanced Drainage Systems Inc nearer its low. Which is the better fit depends on your goals.
| WMS | XBI | |
|---|---|---|
Market Cap | $10.96B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $175.38 | $164.28 |
52-Week Low | $110.99 | $85.16 |
Enterprise Value | $12.53B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WMS (Advanced Drainage Systems) trades at $138.74, down 5.97% on the day, with a bearish technical signal. The company shows solid fundamentals with a 13.98% net income margin and consistent earnings beats in recent quarters, though 2025 revenue was flat at $2.90B. Recent news includes a dividend increase and upcoming Q1 FY2027 results on August 6, 2026.
The stock presents a mixed outlook. Strong profitability and a consensus price target of $184.43 suggest upside potential, but near-term headwinds include a bearish technical setup and projected earnings decline in 2026. Key risks are execution on investments and competitive pressures in the water management sector.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
